Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Teyro Labs Private Limited
483
•Teyro Labs Private Limited•March 27, 2015

Teyro Labs Private Limited – FDA 483, Mar 27, 2015

Record Details

During an inspection conducted from March 23 to March 27, 2015, the U.S. Food and Drug Administration (FDA) issued a Form 483 to Myers Vitamin, Inc., a dietary supplement manufacturer located in West Haven, Utah. The inspection revealed seven significant observations related to the company's adherence to Current Good Manufacturing Practice (cGMP) regulations for dietary supplements, as outlined in 21 CFR Part 111. A critical aspect of these findings is that all seven observations were repeat deficiencies from a previous inspection that concluded on July 10, 2013, indicating a persistent lack of compliance. The main issues identified included a failure to establish specifications for raw materials and finished dietary supplement products, meaning the company lacked defined standards for identity, purity, strength, and composition. Furthermore, Myers Vitamin, Inc. had not established or followed written procedures for critical quality control operations, including material review and disposition, and lacked Master Manufacturing Records and Batch Production Records for its products. The firm also failed to collect required reserve samples of packaged supplements and had no written procedures for handling product complaints. These observations highlight a systemic failure in the company's quality management system. To achieve compliance, Myers Vitamin, Inc. is required to implement robust corrective actions addressing these fundamental deficiencies in its manufacturing processes, quality control, and documentation practices. This is essential to ensure the safety, quality, and integrity of the dietary supplements it produces.

Company
Teyro Labs Private Limited
Inspection date
March 27, 2015
Product type
Drugs
Office
Office of Global Policy and Strategy
People
  • Timothy H. Vo (investigator)
  • Arsen Karapetyan
View Company Profile

ID · dcefd679-ba3a-4b88-ae97-5b9e7b2bda8f

Other documents for Teyro Labs Private Limited
  • 483 - 2025-11-12November 12, 2025
  • 483 - 2023-03-03March 3, 2023

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Teyro Labs Private Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.